TY - JOUR
T1 - Advances in therapeutics for neurodegenerative tauopathies
T2 - Moving toward the specific targeting of the most toxic tau species
AU - Gerson, Julia E.
AU - Castillo-Carranza, Diana L.
AU - Kayed, Rakez
N1 - Publisher Copyright:
© 2014 American Chemical Society.
PY - 2014/9/17
Y1 - 2014/9/17
N2 - Neurodegenerative disease is one of the greatest health concerns today and with no effective treatment in sight, it is crucial that researchers find a safe and successful therapeutic. While neurofibrillary tangles are considered the primary tauopathy hallmark, more evidence continues to come to light to suggest that soluble, intermediate tau aggregates - tau oligomers - are the most toxic species in disease. These intermediate tau species may also be responsible for the spread of pathology, suggesting that oligomeric tau may be the best therapeutic target. Here, we summarize results for the modulation of tau by molecular chaperones, small molecules and aggregation inhibitors, post-translational modifications, immunotherapy, other techniques, and future directions. (Figure Presented).
AB - Neurodegenerative disease is one of the greatest health concerns today and with no effective treatment in sight, it is crucial that researchers find a safe and successful therapeutic. While neurofibrillary tangles are considered the primary tauopathy hallmark, more evidence continues to come to light to suggest that soluble, intermediate tau aggregates - tau oligomers - are the most toxic species in disease. These intermediate tau species may also be responsible for the spread of pathology, suggesting that oligomeric tau may be the best therapeutic target. Here, we summarize results for the modulation of tau by molecular chaperones, small molecules and aggregation inhibitors, post-translational modifications, immunotherapy, other techniques, and future directions. (Figure Presented).
KW - Immunotherapy
KW - Molecular chaperones
KW - Oligomers
KW - Small molecules
UR - http://www.scopus.com/inward/record.url?scp=84924980333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924980333&partnerID=8YFLogxK
U2 - 10.1021/cn500143n
DO - 10.1021/cn500143n
M3 - Review article
C2 - 25075869
AN - SCOPUS:84924980333
SN - 1948-7193
VL - 5
SP - 752
EP - 769
JO - ACS chemical neuroscience
JF - ACS chemical neuroscience
IS - 9
ER -